About Us
EnoGene Biotech Co. Ltd, is a biological high-tech corporation that specializes in developing and production of antibody related products for biochemistry, molecular biology, immunology and other reagents in general laboratory use. EnoGene Biotech possesses advanced equipments, a highly experienced professional team, and the first class laboratory technology to offer the best products and services to universities, colleges, academes and institutes. At the same time, EnoGene Biotech focuses on transferring and developing the innovative research findings to reagent products. We will contribute to the development of biomedical research with our continuous new products.
At present, we have established the full-blown technology for monoclonal and polyclonal antibodies development. Meanwhile, we provide researchers with biotech services like peptide synthesis, monoclonal antibody development, polyclonal antibody development, antibody validation by Western Blot, ELISA, flowcytometry, immunohistochemistry, etc. Through normative experiment operation, sternly control of the quality, and the full-blown technology, we will provide researchers high-qualified biotech services, saving your time and energy for more secrets in the vast field of life science.
Innovation drives EnoGene continuous growth in the life Science technology field, providing the latest and most advanced services of this domain. In short, we can supply you with constructive suggestions and comprehensive solutions to the problems you meet during antibody development. EnoGene is committed to developing itself to the world's provider of antibodies and antibody related services with the best quality and the most competitive-edge prices. We're sure that EnoGene will become your right hand and a partner you can trust.
EnoGene™,Enjoy Innovation……
Piwil2 Inhibits Keratin 8 Degradation through Promoting p38-Induced Ph…
타이틀
저자
게시일
게시장소
ABSTRACT
The piwi-like 2 (piwil2) gene is widely expressed in tumors and protects cells from apoptosis induced by a variety of stress stimuli. However, the role of Piwil2 in Fas-mediated apoptosis remains unknown. Here, we present evidence that Piwil2 inhibits Fas-mediated apoptosis. By a bacterial two-hybrid screening, we identify a new Piwil2-interacting partner, keratin 8 (K8), a major intermediate filament protein protecting the cell from Fas-mediated apoptosis. Our results show that Piwil2 binds to K8 and p38 through its PIWI domain and forms a Piwil2/K8/P38 triple protein-protein complex. Thus, Piwil2 increases the phosphorylation level of K8 Ser-73 and then inhibits ubiquitin-mediated degradation of K8. As a result, the knockdown of Piwil2 increases the Fas protein level at the membrane. In addition to our previous finding that Piwil2 inhibits the expression of p53 through the Src/STAT3 pathway, here we demonstrate that Piwil2 represses p53 phosphorylation through p38. Our present study indicates that Piwil2 plays a role in Fas-mediated apoptosis for the first time and also can affect p53 phosphorylation in tumor cells, revealing a novel mechanism of Piwil2 in apoptosis, and supports that Piwil2 plays an active role in tumorigenesis.
FOOTNOTES
S. Jiang, L. Zhao, and Y. Lu contributed equally to this work.
Published ahead of print 11 August 2014